Vetoquinol SA

V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
  • TickerVETO
  • ISINFR0004186856
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

1 director sold

A director at Vetoquinol sold 1,300 shares at 60.322EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Christophe-Raphaël Ganet

Vetoquinol : CA T2 2019 poussif – Marge S1 inférieure à notre attente – Révision en baisse de nos estimations – OC : 59 € vs 60 €

>CA T2: +2.9% - Baisse de la MOP de près de 180 pb - Les ventes du T2 ont atteint 92.8 M€, soit +2.9%. La croissance externe au Brésil génère une croissance de 2.7% ; l’impact positif de change (+1.6%) compense le repli observé sur le territoire Asie/Pacifique.Sur le S1 2019, le ROC se situe à 17.9 M€, en repli de 12.9% par rapport à la même période de l’exercice précédent ; il s’établit à 9.7% du CA.Vétoquinol affiche, à fin juin 2019, une situation de trés...

Christophe-Raphaël Ganet

Vetoquinol : CA T2 2019 poussif – Marge S1 inférieure à notre attente – Révision en baisse de nos estimations – OC : 59 € vs 60 €

>CA T2: +2.9% - Baisse de la MOP de près de 180 pb - Les ventes du T2 ont atteint 92.8 M€, soit +2.9%. La croissance externe au Brésil génère une croissance de 2.7% ; l’impact positif de change (+1.6%) compense le repli observé sur le territoire Asie/Pacifique.Sur le S1 2019, le ROC se situe à 17.9 M€, en repli de 12.9% par rapport à la même période de l’exercice précédent ; il s’établit à 9.7% du CA.Vétoquinol affiche, à fin juin 2019, une situation de trés...

Christophe-Raphaël Ganet

Vetoquinol : Q1 2019 sales moderated by the reproduction range in the Americas - no momentum effect

>Q1 sales: € 90.9m, up +3.7% and 2.3% at constant currencies - Companion animal products (57% of sales) were up +7.5% (+5.2% at cc.) while production animal products were down 0.8% (-1.3% at cc.).VETO posted good levels of growth in Europe and Asia1ePacific with organic growth of +5.9% and +9.1%, respectively, but posted a fall in sales in the Americas (-2.6% reported), owing to a “a one-off shift of cattle reproduction product sales between periods”.Sales of...

Christophe-Raphaël Ganet

Vetoquinol : CA T1 2019 modéré par la gamme reproduction sur les Amériques - Pas d’effet momentum

>CA T1 : 90.9 M€ soit +3.7% et 2.3% à tcc - Les Animaux de compagnie (57% du CA) seraient en croissance de 7.5% (+5.2% à tcc.) tandis que les Animaux de production afficheraient une baisse de 0.8% (-1.3% à tcc.).VETO enregistre de bons niveaux de croissance en Europe et en Asie/Pacifique avec une croissance organique de respectivement de +5.9% et +9.1% mais affiche un tassement de son CA sur les Amériques (-2.6% à données publiées), en raison d’un « effet de liss...

Christophe-Raphaël Ganet

Vetoquinol : Feedback from analysts’ meeting: a solid trajectory but less upside in the short term

>2019: a year at cruising speed? - From the meeting, we retain the following points:1- Sales guidance: no official guidance but we understand that 2019 sales up +3/5% on an organic basis would be a legitimate target given growth in the animal health market (around +4% with significantly diverging trends by region as Europe, which accounts for almost 50% of Vétoquinol’s sales, is forecast up 1.5%-2%e due to measures targeting the limiting of antibiotic use,  unli...

Christophe-Raphaël Ganet

Vetoquinol : Feedback réunion d’analystes : trajectoire solide mais moins d’upside CT

>2019 : une année régime de croisière ? - Au sortir de la réunion, nous retenons :1- Guidances de CA : pas de guidance officielle mais nous comprenons qu'un CA 2019 à +3/5% organique serait un objectif légitime compte tenu de la croissance du marché de la santé animale (autour de +4% avec pas mal de contraste par zone puisque l'Europe, proche de 50% du CA de Vétoquinol, ne progresse que de 1,5%/2%e en raison des mesures visant à limiter l'usage des antibiotiques,...

1 director sold

A director at Vetoquinol sold 1,300 shares at 60.322EUR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hela Zarrouk
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 04/18/2019

...

Antoine Boivin-Champeaux ...
  • Aurelien Sivignon
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Hela Zarrouk
  • Laurence Hofmann
  • Louis Boujard
  • Philippe Ourpatian
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 18/04/2019

...

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 03/22/2019

...

Anis Zgaya ...
  • Baptiste Lebacq
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Jeremy Garnier
  • Louis Boujard
  • Nicolas Thorez
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 22/03/2019

...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Geoffroy Michalet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 03/08/2019 Date Performance since listing Date Performance since listing

Sixt Leasing, an independent player in the German vehicle leasing and fleet management market, stands out for its strong momentum in the online retail and fleet management segments and its capacity to handle the diesel risk effectively. These strengths should pave the way for buoyant growth over the coming years (2018-2021e CAGR of +8% for revenue and 15% for pre-tax profit) and a rerating of the stock (target price € 18.1, i.e. 34% upside). We are initiating coverage of the stock wit...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Onxeo SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Onxeo SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This ...

MarketLine Department

Dechra Pharmaceuticals PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Dechra Pharmaceuticals PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Dechra Pharmaceuticals PLC since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competiti...

Florian Béchaz

Vétoquinol S.A. - Assemblée Générale des actionnaires du 21 mai 2019

Proxinvest attire l'attention des actionnaires sur les points suivants : Tout d'abord, notons que le Conseil d'administration de la société est largement composé par la famille Frechin, actionnaire de contrôle, qui est représentée par 4 sièges sur 8 (50%). Par ailleurs, Proxinvest regrette que la société maintienne la possibilité de l'usage de ses délégations financières en période d'offre publique, ce qui n'est pas favorable aux intérêts des actionnaires puisque cela peut être considéré comme la mise en place d'un arsenal anti-OPA. Enfin, la communication de la société concernant les rémuné...

Jehanne Leroy

Proxy Report - 29/05/2018

Proxinvest attire l'attention des actionnaires sur les points suivants : Tout d'abord, notons que le Conseil d'administration de la société est largement dominé par la famille Frechin, actionnaire de contrôle, qui est représentée par 5 sièges sur 9 (55,6%). Par ailleurs, Proxinvest regrette que la société maintienne la possibilité de l'usage de ses délégations financières en période d'offre publique, ce qui n'est pas favorable aux intérêts des actionnaires puisque cela peut être considéré comme la mise en place d'un arsenal anti-OPA. Enfin, la communication de la société concernant les rémun...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch